PMID- 33837901 OWN - NLM STAT- MEDLINE DCOM- 20210519 LR - 20210519 IS - 1573-4978 (Electronic) IS - 0301-4851 (Linking) VI - 48 IP - 3 DP - 2021 Mar TI - Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer. PG - 2543-2552 LID - 10.1007/s11033-021-06302-3 [doi] AB - One of the most recent of tumor molecular characterization approaches is the microRNA (miR) expression profile. No single marker is sufficiently accurate for clinical use. Numerous biomarkers panels were created for three main purposes: tumor subtype, classification and, early detection, and prediction of tumor responses to treatment and prognosis of patients. miR-21-5p and miR-126-3p have received special attention because of their relationship with many cancer sites such as lung cancer, colorectal cancer, and renal cell carcinoma. We aimed to study their diagnostic and prognostic utility in lung cancer patients. Serum carcinoembryonic antigen (CEA) level was measured using an enzyme-linked immunosorbent assay (ELISA) technique. The expression levels of miR-21-5p and miR-126-3p were determined by real-time PCR in 60 non small cell lung cancer (NSCLC) patients and 40 healthy controls to detect diagnostic utility. Moreover, it was correlated with all disease clinicopathological characters and patient survival. Higher miR-21-5p and lower miR-126-3p levels were found in lung cancer patients than in controls. The sensitivity of CEA and miR-21-5p and miR-126-3p were 78.3, 96.7, and 90% at cutoff points 7.5, 2.35, and 2.175, respectively to distinguish NSCLC patients from controls. On combining both miR-21-5p and miR-126-3p, an improvement of sensitivity to 97% was noted. For patients, miR-21-5P increased significantly with metastatic stage and the highest grade (GIII). There was significantly longer overall survival (OS) among patients with early stages, lower grades GI&II, low miR-21-5p, and high miR-126-3p. miR-126-3p and presence of metastasis, the last two factors were the independent factors affecting OS with a hazard ratio of 0.26 (95% CI: 0.06-1.09) and 3.64 (95% CI: 1.22-16.5), respectively. Circulating miR-21-5p and miR-126-3p may play a significant role in diagnosis and prognosis in NSCLC patients. FAU - Soliman, Shimaa El-Shafey AU - Soliman SE AUID- ORCID: 0000-0003-3919-3818 AD - Faculty of Medicine, Medical Biochemistry and Molecular Biology Department, Menoufia University, Shebin elKom, Menoufia, 32511, Egypt. ahmedlabeebhikal@gmail.com. AD - Medical Biochemistry Unit, Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia. ahmedlabeebhikal@gmail.com. FAU - Abdelaleem, A H AU - Abdelaleem AH AD - Faculty of Science, Chemistry Department, Menoufia University, Menoufia, Egypt. FAU - Alhanafy, Alshimaa Mahmoud AU - Alhanafy AM AD - Faculty of Medicine, Department of Clinical Oncology and Nuclear Medicine, Menoufia University, Menoufia, Egypt. FAU - Ibrahem, Reda Abdel Latif AU - Ibrahem RAL AD - Department of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt. FAU - Elhaded, Asmaa S Abo AU - Elhaded ASA AD - Chemist at Faculty of Science, Menoufia University, Menoufia, Egypt. FAU - Assar, Mohamed F A AU - Assar MFA AD - Biochemistry Division of Chemistry Department, Faculty of Science, Menoufia University, Menoufia, Egypt. LA - eng PT - Journal Article DEP - 20210410 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Circulating MicroRNA) RN - 0 (MIRN126 microRNA, human) RN - 0 (MIRN21 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Carcinoma, Non-Small-Cell Lung/*blood/*genetics/pathology MH - Circulating MicroRNA/*blood/*genetics MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Lung Neoplasms/*blood/*genetics/pathology MH - Male MH - MicroRNAs/*blood/genetics MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Grading MH - Prognosis MH - Proportional Hazards Models MH - Survival Analysis MH - Young Adult OTO - NOTNLM OT - Lung cancer OT - MiR-126-3p OT - MiR-21-5p OT - RT-PCR EDAT- 2021/04/11 06:00 MHDA- 2021/05/20 06:00 CRDT- 2021/04/10 12:12 PHST- 2020/11/16 00:00 [received] PHST- 2021/03/18 00:00 [accepted] PHST- 2021/04/11 06:00 [pubmed] PHST- 2021/05/20 06:00 [medline] PHST- 2021/04/10 12:12 [entrez] AID - 10.1007/s11033-021-06302-3 [pii] AID - 10.1007/s11033-021-06302-3 [doi] PST - ppublish SO - Mol Biol Rep. 2021 Mar;48(3):2543-2552. doi: 10.1007/s11033-021-06302-3. Epub 2021 Apr 10.